Efficacy and Safety of Glimepiride As Initial Treatment in Chinese Patients with Type 2 Diabetes Mellitus

Xiao-hui Guo,Xiao-feng Lv,Ping Han,Xiu-zhen Zhang,Hua-zhang Yang,Wen-ruo Duan,Yan Gao

DOI: https://doi.org/10.1185/03007995.2013.765396

2013-01-01

Current Medical Research and Opinion

Abstract:Objective:To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients in China.Methods:This is a multi-center, open-label, single arm study. A total of 391 subjects were enrolled to receive glimepiride treatment for 16 weeks, the initiation dose was 1 mg/d, with titration to 2 mg/d and 4 mg/d according to the fasting blood glucose (FBG) level measured at each visit. The change in HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), HOMA-IR, weight, waist circumference and the incidence of hypoglycemia were evaluated. An exploratory analysis was conducted to identify the potential population prone to achieve target glycemic control.Results:HbA1c was reduced significantly from 8.6 +/- 1.6% to 6.9 +/- 0.9% (p<0.001); 60.9% of the subjects achieved HbA1c <7% at study endpoint. The reduction in FPG and 2hPPG were 2.3 mmol/L and 4.4 mmol/L (p<0.001) respectively. Insulin resistance was improved significantly with HOMA-IR decreasing from 2.5 +/- 2.3 to 2.2 +/- 1.9 (p=0.009). The incidence of confirmed hypoglycemia (BG <= 3.9 mmol/L) was 3.1%.Conclusions:Glimepiride treatment as initial mono-therapy could effectively improve blood glucose control in type 2 diabetic patients, with a favorable safety profile. Lack of control group was the major limitation of this study.